Viridium Announces Grants of Options and RSUs
Calgary, Alberta (FSCwire) - Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR, OTCPink: MRRBF) announces that on October 6, 2017 it has granted an aggregate of 1,350,000 options to purchase common shares of the Company exercisable at a price of $0.60 per share for a period of five years, to officers, employees and consultants of the Company (the “Options”). In addition, it has been agreed that, if any of the Options are not permitted to be granted by the TSX Venture Exchange, the Options (or such number as may be permitted) shall constitute RSUs on the terms described below and pursuant to the Company’s RSU Plan.
Additionally, on October 6, 2017 the Company granted a total of 2,771,375 restricted share units ("RSUs") to the directors, officers, employees and consultants of the Company under the terms of the Company's restricted share unit plan (the "RSU Plan"). The directors and officers have been granted 1,747,750 RSUs of the aforesaid amount with the remaining 1,023,625 RSUs having been granted to employees and consultants.
Each RSU entitles the holder to acquire one common share of the Company by delivering an exercise notice in accordance with the RSU Plan. The RSU grant follows the guidelines of the RSU Plan. The RSUs do not vest until after January 1, 2018 and will vest thereafter when certain performance milestones are met. In addition, in the event that the RSUs are not authorized by the TSX Venture Exchange they shall constitute a grant of Options on the Option terms as indicated above (including an exercise price of $0.60). The selected milestones for the RSUs vary based upon the duties and responsibility of the recipient. The RSUs granted to the directors and officers (except for one officer) of the Company do not vest until after January 1, 2018 and the Company’s affiliate (Experion Biotechnologies Inc.) receives its amended ACMPR license to sell cannabis. In regard to the RSUs granted to Jarrett Malnarick (the COO of Viridium) the RSUs do not vest until after January 1, 2017 and the first harvest of the cannabis crop from the current ACMPR licensed facility.
The RSU Plan was approved by the shareholders at the Company's AGM held on July 14, 2017 and has been posted on SEDAR.com.
About Viridium
Viridium owns a controlling interest in Experion Biotechnologies Inc. (“Experion”). Experion has been granted by Health Canada a ACMPR license to produce cannabis and it is proceeding to meet the Health Canada requirements to amend its current license to include a license to sell. Viridium has been advised that it will commence trading on the TSX Venture Exchange (symbol: VIR) and on the OTCPink (symbol: MRRBF) on October 11, 2017.
More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.
Disclosure
The TSX Venture Exchange has in no way passed upon the merits of the proposed Reverse Take-over Transaction and has neither approved nor disapproved the contents of this news release.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
For further information:
VIRIDIUM PACIFIC GROUP LTD.
John Zang
Corporate Secretary
Telephone: 403 680 9264
Email: jzanglaw@gmail.com
To view this press release as a PDF file, click onto the following link:public://news_release_pdf/Viridium10102017-2.pdf
Source: Viridium Pacific Group Ltd. (TSX Venture:VIR)
To follow Viridium Pacific Group Ltd. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2017 Filing Services Canada Inc.